TC-6683, AZD1446

TC-6683, also known as AZD1446, is a potent and selective inhibitor of phosphodiesterase 10A (PDE10A), an enzyme that plays a key role in regulating the levels of cyclic nucleotides, such as cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), in the brain. By inhibiting PDE10A, TC-6683 increases the levels of cAMP and cGMP, which in turn enhances the activity of neurotransmitters that are involved in a variety of brain functions, including cognition, mood, and movement. TC-6683 has shown promising results in preclinical studies as a potential treatment for a range of neurological and psychiatric disorders, such as schizophrenia, Huntington's disease, Parkinson's disease, and depression. In addition, TC-6683 has demonstrated excellent safety and tolerability profiles in both animals and humans, making it a promising candidate for further development. Chemically, TC-6683 is a small molecule with a molecular weight of 477.5 g/mol and a chemical formula of C23H23F2N3O2. It has a half-life of approximately 12 hours in humans and is metabolized primarily by the liver. TC-6683 is administered orally, typically in the form of a tablet or capsule, and is rapidly absorbed into the bloodstream. It is important to note that TC-6683 is still in the experimental stages of development, and further clinical trials will be required to determine its safety and efficacy in humans.